No Prescription |
 |
 | ||
|
CANESTEN Duo Cream |
|
| ||
No Prescription » Prescription Drugs 3 » CANESTEN Duo Cream Canesten Fluconazole Capsule & Clotrimazole Cream Duo is indicated for vaginal candidiasis.The cream can also be used for relief of external itching/irritation and the management Candida vulvovaginitis or infection of the peri-anal area. Buy CANESTEN Duo Cream and other Prescription Drugs 3 products online at Medstore. 5457
About CANESTEN Duo Cream: Product Type: Prescription Drugs 3 CANESTEN Duo Cream + Cap ( Generic FLUCONAZOLE CAPSULE & CLOTRIMAZOLE CREAM DUO) CANESTEN Duo Cream + Cap (Generic FLUCONAZOLE CAPSULE & CLOTRIMAZOLE CREAM DUO) Generic FLUCONAZOLE CAPSULE & CLOTRIMAZOLE CREAM DUO 150mg/10mg/gm 1 Cap / 10gm Tube Generic FLUCONAZOLE CAPSULE & CLOTRIMAZOLE CREAM DUO CANESTEN Duo Cream + Cap
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
